Translational study of the antibiofilm activity of lysin CF-301 in an infected hemodialysis catheter from patient with suspected Staph aureus bacteremia Presented at 28th ECCMID, April 23, 2018
Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA, Europe and South America Presented at ID Week 2017, October 6, 2017
Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus Presented at ID Week 2017, October 6, 2017
Population Phamacokinetic-Pharmacodynamic Assessment of Cardiac Safety Endpoints for CF-301, a First-In-Class Antibacterial Lysin Presented at ASM Microbe 2017, June 3, 2017
Inflammatory Markers in a Phase 1 Placebo Controlled Dose Escalating Study of Intravenous Doses of CF-301 in Human Subjects Presented at ASM Microbe 2017, June 2, 2017
Low Propensity of Resistance Development In Vitro in Staphylococcus aureus with Lysin CF-301 Presented at ASM Microbe 2017, June 2, 2017
Quality Control Studies of CF-301 versus Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 Presented at ASM Microbe 2017, June 2, 2017
Development of an Antimicrobial Susceptibility Test (AST) for the Antistaphylococcal Lysin CF-301 Presented at 27th ECCMID, April 22, 2017
Long Term Immunology Results of a Phase 1 Placebo Controlled Dose Escalating Study to Examine the Safety of CF-301 in Human Volunteers Presented at 27th ECCMID, April 22, 2017
